idegasp

Insulin Aspart

Products Insulin aspart is marketed as an injectable (NovoRapid, USA: NovoLog). It has been approved in many countries since 1999. The fixed combination IDegAsp (insulin aspart + insulin degludec, Ryzodeg) was registered in many countries and in the EU in 2013. In 2017, Fiasp ultra-fast-acting, a very fast-acting insulin aspart, was also approved. With the … Insulin Aspart

Insulin Degludec

Products Insulin degludec is commercially available as a solution for injection (Tresiba). It is also combined fixed with insulin aspart (Ryzodeg, see under IDegAsp). It was newly approved in many countries in March 2013. In 2014, a fixed combination with liraglutide was registered (Xultophy); see under IDegLira. Structure and properties Insulin degludec has essentially the … Insulin Degludec